RT @synovialjoints: Abatacept use in individuals at risk of RA reduced the rate of progression to RA during the treatmen
Tweet Content
Abatacept use in individuals at risk of RA reduced the rate of progression to RA during the treatment phase and împrovement in clinical symptoms over 2 years in the APIPPRA trial by Cope A, Abstr#OP0130 https://t.co/k0SFDHBRE9
Show on Archive Page
On
Display in Search Results
On
PDQ
Off